17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Emerald, Failure Patients, Hematide, Lead, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Emerald, Failure Patients, Hematide, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
11 Nov 08 Interim Analysis Of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety For Corthera’s Relaxin In Acute Heart Failure
Corthera Inc. announced that an interim analysis of top-line data from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, international study, showed favorable efficacy and safety for relaxin, the company’s investigational drug for treatment of acute heart failure. The interim Phase II results were presented by John R. Teerlink, M.D.
(more…)
Tags: Acute Heart Failure, Amp, Efficacy, Heart Failure, Interim Analysis, Interim Phase, Investigational Drug, Phase Ii, Relax, Relaxin, Treatment Failure
05 Nov 08 Affymax Completes Enrollment In PEARL 2, 2nd Of 4 Phase 3 Clinical Trials Of Hematide To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 2 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 490 non-dialysis patients from over 60 sites in the United States and Europe.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Europe, Failure Patients, Hematide, Lead, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
19 Sep 08 The ImCardia™ Is One Step Closer To Becoming A New Treatment Paradigm For Diastolic Heart Failure
CorAssist, a developer of novel therapeutic devices for Diastolic Heart Failure (DHF), announced today its flagship product, the ImCardia™, significantly improved DHF parameters in a first-of-its-kind preclinical study and has shown preliminary safety in two humans after three months follow up.
(more…)
Tags: Developer, Dhf, Flagship Product, Heart Failure, Novel, Parameters, Therapeutic Devices, Three Months, Treatment Failure, Treatment Paradigm
